Hussain Saad Abdulrahman, Utba Rabab Mohammed, Assumaidaee Ajwad Muhammad
Faculty of Pharmacy, Alrafidain University College, Baghdad, Iraq.
Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
Med Arch. 2017 Aug;71(4):251-255. doi: 10.5455/medarh.2017.71.251-255.
In addition to its role in regulation of blood pressure, fluid and electrolyte homeostasis, the renin-angiotensin system (RAS) components were expressed in many other tissues suggesting potential roles in their functions.
The present study aims to evaluate the protective effect aliskiren, when used alone or in combination with azilsartan against high fat diet-induced liver disease in rats.
Thirty-two Wistar male rats, weighing 150-200 gm were allocated evenly into four groups and treated as follow: group I, rats were fed a specially formulated high-fat diet for 8 weeks to induce non-alcoholic liver disease and considered as control group; groups II, III and IV, the rats were administered azilsartan (0.5 mg/kg), aliskiren (25 mg/kg) or their combination orally via gavage tube once daily, and maintained on high fat diet for 8 weeks. The possible treatment outcome was evaluated through measuring serum levels of glucose, insulin, lipid profile, TNF-α, IL-1β and liver enzymes. Additionally, the liver tissue contents of glycogen and lipids and histological changes were also evaluated.
The results showed that azilsartan significantly improves the studied markers greater than aliskiren, and their combination o has no additive or synergistic effects on the activity of each one of them.
Both azilsartan and aliskiren protects the rats against high-fat diet induced NAFLD with predominant effects for the former, and their combination showed no beneficial synergistic or additive effects.
肾素-血管紧张素系统（RAS）的组成部分除了在调节血压、体液和电解质平衡中发挥作用外，还在许多其他组织中表达，提示其在这些组织功能中可能发挥作用。
本研究旨在评估阿利吉仑单独使用或与阿齐沙坦联合使用对高脂饮食诱导的大鼠肝病的保护作用。
将32只体重150-200克的雄性Wistar大鼠平均分为四组，进行如下处理：第一组，大鼠喂食特制高脂饮食8周以诱导非酒精性肝病，作为对照组；第二、三、四组，大鼠每天经灌胃管口服给予阿齐沙坦（0.5毫克/千克）、阿利吉仑（25毫克/千克）或二者联合用药，并维持高脂饮食8周。通过测量血清葡萄糖、胰岛素、血脂谱、肿瘤坏死因子-α、白细胞介素-1β和肝酶水平评估可能的治疗效果。此外，还评估了肝组织中糖原和脂质的含量以及组织学变化。
结果显示，阿齐沙坦对所研究指标的改善作用明显大于阿利吉仑，二者联合使用对它们各自的活性没有相加或协同作用。
阿齐沙坦和阿利吉仑均可保护大鼠免受高脂饮食诱导的非酒精性脂肪性肝病影响，前者作用更显著，二者联合使用未显示出有益的协同或相加作用。
